282 related articles for article (PubMed ID: 29352101)
1. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
Wehrum T; Beume LA; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S
Neurology; 2018 Feb; 90(7):e601-e605. PubMed ID: 29352101
[TBL] [Abstract][Full Text] [Related]
2. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
3. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
4. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
5. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
Richter S; Wagner B; Celius EG
J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
[No Abstract] [Full Text] [Related]
6. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
8. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
9. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
[TBL] [Abstract][Full Text] [Related]
11. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
12. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
13. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
14. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
15. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
16. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
17. Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses.
Hilger C; Riedhammer C; Orsó E; Weissert R
Front Immunol; 2020; 11():563645. PubMed ID: 33133074
[TBL] [Abstract][Full Text] [Related]
18. Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
Akgün K; Blankenburg J; Marggraf M; Haase R; Ziemssen T
Front Immunol; 2020; 11():56. PubMed ID: 32082320
[No Abstract] [Full Text] [Related]
19. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
